Sage Therapeutics (SAGE) Revenue & Revenue Breakdown
Sage Therapeutics Revenue Highlights
Latest Revenue (Y)
$86.45M
Latest Revenue (Q)
$11.87M
Main Segment (Y)
Product
Sage Therapeutics Revenue by Period
Sage Therapeutics Revenue by Year
Date | Revenue | Change |
---|---|---|
2023-12-31 | $86.45M | 1024.84% |
2022-12-31 | $7.69M | 21.85% |
2021-12-31 | $6.31M | -99.43% |
2020-12-31 | $1.11B | 16123.06% |
2019-12-31 | $6.87M | -92.39% |
2018-12-31 | $90.27M | 100.00% |
2017-12-31 | - | 100.00% |
2016-12-31 | - | 100.00% |
2015-12-31 | - | 100.00% |
2014-12-31 | - | 100.00% |
2013-12-31 | - | 100.00% |
2012-12-31 | - | - |
Sage Therapeutics Revenue by Quarter
Date | Revenue | Change |
---|---|---|
2024-09-30 | $11.87M | 37.17% |
2024-06-30 | $8.65M | 9.52% |
2024-03-31 | $7.90M | -89.87% |
2023-12-31 | $77.97M | 2770.84% |
2023-09-30 | $2.72M | 9.78% |
2023-06-30 | $2.47M | -24.89% |
2023-03-31 | $3.29M | 14.97% |
2022-12-31 | $2.87M | 64.75% |
2022-09-30 | $1.74M | 15.86% |
2022-06-30 | $1.50M | -5.12% |
2022-03-31 | $1.58M | -3.65% |
2021-12-31 | $1.64M | 14.03% |
2021-09-30 | $1.44M | -12.36% |
2021-06-30 | $1.64M | 3.79% |
2021-03-31 | $1.58M | -99.86% |
2020-12-31 | $1.11B | 67574.56% |
2020-09-30 | $1.64M | 50.51% |
2020-06-30 | $1.09M | -52.36% |
2020-03-31 | $2.29M | 16.63% |
2019-12-31 | $1.96M | -45.10% |
2019-09-30 | $3.57M | 308.93% |
2019-06-30 | $873.00K | 87.74% |
2019-03-31 | $465.00K | 70.33% |
2018-12-31 | $273.00K | 100.00% |
2018-09-30 | - | -100.00% |
2018-06-30 | $90.00M | 100.00% |
2018-03-31 | - | 100.00% |
2017-12-31 | - | 100.00% |
2017-09-30 | - | 100.00% |
2017-06-30 | - | 100.00% |
2017-03-31 | - | 100.00% |
2016-12-31 | - | 100.00% |
2016-09-30 | - | 100.00% |
2016-06-30 | - | 100.00% |
2016-03-31 | - | 100.00% |
2015-12-31 | - | 100.00% |
2015-09-30 | - | 100.00% |
2015-06-30 | - | 100.00% |
2015-03-31 | - | 100.00% |
2014-12-31 | - | 100.00% |
2014-09-30 | - | 100.00% |
2014-06-30 | - | 100.00% |
2014-03-31 | - | 100.00% |
2013-12-31 | - | 100.00% |
2013-09-30 | - | 100.00% |
2013-06-30 | - | 100.00% |
2013-03-31 | - | - |
Sage Therapeutics Revenue Breakdown
Sage Therapeutics Revenue Breakdown by Product
Annual Revenue by Product
Product/Service | Dec 23 | Dec 22 | Dec 21 | Dec 20 | Dec 19 |
---|---|---|---|---|---|
Collaboration Revenue Related Party | $824.00K | - | - | - | - |
Product | $10.45M | $7.69M | $6.31M | $6.70M | $3.96M |
Other Collaboration Revenue | $177.00K | - | - | - | - |
Collaboration Revenue | - | - | - | $1.11B | $2.91M |
Latest
Quarterly Revenue by Product
Product/Service | Sep 24 | Jun 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Other Collaboration Revenue | $634.00K | $634.00K | - | - | - | - | - | - | - | - | - | - | - | - |
Product | $843.00K | $600.00K | $1.98M | $2.72M | $2.46M | $3.29M | $1.58M | $1.69M | $1.64M | $1.09M | $2.29M | $1.96M | $1.48M | $519.00K |
Collaboration Revenue Related Party | $11.03M | $7.42M | - | - | - | - | - | - | - | - | - | - | - | - |
Collaboration Revenue | - | - | - | $14.00K | - | $2.09M | $354.00K | - | - | - | - | - | - | - |
Latest
Sage Therapeutics Peer Comparison by Revenue
Ticker | Company | Last Year Revenue | Last Quarter Revenue |
---|---|---|---|
INCY | Incyte | $3.70B | $962.99M |
ALNY | Alnylam Pharmaceuticals | $1.83B | $420.15M |
AMLX | Amylyx Pharmaceuticals | $380.79M | $416.00K |
APLS | Apellis Pharmaceuticals | $366.28M | $176.57M |
IMCR | Immunocore | $249.43M | $75.40M |
BPMC | Blueprint Medicines | $249.38M | $128.18M |
SAGE | Sage Therapeutics | $86.45M | $11.87M |
ARVN | Arvinas | $78.50M | $102.40M |
KRYS | Krystal Biotech | $50.70M | $83.84M |
RLAY | Relay Therapeutics | $25.55M | - |
STOK | Stoke Therapeutics | $8.78M | $4.89M |
PLRX | Pliant Therapeutics | $1.58M | - |
BDTX | Black Diamond Therapeutics | - | - |
NUVL | Nuvalent | - | - |
DAWN | Day One Biopharmaceuticals | - | $20.07M |
DMAC | DiaMedica Therapeutics | - | - |
CERE | Cerevel Therapeutics | - | - |
MDGL | Madrigal Pharmaceuticals | - | $62.17M |
TERN | Terns Pharmaceuticals | - | - |
VTYX | Ventyx Biosciences | - | - |
AKRO | Akero Therapeutics | - | - |